🚀 VC round data is live in beta, check it out!
Vicore Pharma Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vicore Pharma Holding and similar public comparables like Organogenesis, Santhera Pharma, Avalo Therapeutics, Zentalis Pharma and more.
Vicore Pharma Holding Overview
About Vicore Pharma Holding
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Founded
2000
HQ
Employees
29
Website
Sectors
Financials (LTM)
EV
$197M
Vicore Pharma Holding Financials
Vicore Pharma Holding reported last 12-month revenue of $463K and negative EBITDA of ($48M).
In the same LTM period, Vicore Pharma Holding generated $463K in gross profit, ($48M) in EBITDA losses, and had net loss of ($48M).
Revenue (LTM)
Vicore Pharma Holding P&L
In the most recent fiscal year, Vicore Pharma Holding reported revenue of $415K and EBITDA of ($46M).
Vicore Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $463K | XXX | $415K | XXX | XXX | XXX |
| Gross Profit | $463K | XXX | $415K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | ($48M) | XXX | ($46M) | XXX | XXX | XXX |
| EBITDA Margin | (10279%) | XXX | (11053%) | XXX | XXX | XXX |
| EBIT Margin | (10501%) | XXX | (11051%) | XXX | XXX | XXX |
| Net Profit | ($48M) | XXX | ($46M) | XXX | XXX | XXX |
| Net Margin | (10410%) | XXX | (11189%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vicore Pharma Holding Stock Performance
Vicore Pharma Holding has current market cap of $324M, and enterprise value of $197M.
Market Cap Evolution
Vicore Pharma Holding's stock price is $1.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $324M | 3.3% | XXX | XXX | XXX | $-0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVicore Pharma Holding Valuation Multiples
Vicore Pharma Holding trades at 426.1x EV/Revenue multiple, and (4.1x) EV/EBITDA.
EV / Revenue (LTM)
Vicore Pharma Holding Financial Valuation Multiples
As of April 18, 2026, Vicore Pharma Holding has market cap of $324M and EV of $197M.
Equity research analysts estimate Vicore Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vicore Pharma Holding has a P/E ratio of (6.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $324M | XXX | $324M | XXX | XXX | XXX |
| EV (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV/Revenue | 426.1x | XXX | 474.7x | XXX | XXX | XXX |
| EV/EBITDA | (4.1x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.1x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 426.1x | XXX | 474.7x | XXX | XXX | XXX |
| P/E | (6.7x) | XXX | (7.0x) | XXX | XXX | XXX |
| EV/FCF | (5.8x) | XXX | (8.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vicore Pharma Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vicore Pharma Holding Margins & Growth Rates
Vicore Pharma Holding's revenue in the last 12 month grew by 367%.
Vicore Pharma Holding's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.7M for the same period.
Vicore Pharma Holding's rule of 40 is (5764%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vicore Pharma Holding's rule of X is (5598%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Vicore Pharma Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 367% | XXX | 111% | XXX | XXX | XXX |
| EBITDA Margin | (10279%) | XXX | (11053%) | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (5764%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (5598%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1813% | XXX | 1813% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10060% | XXX | 10418% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12006% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vicore Pharma Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vicore Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Santhera Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentalis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| LENZ Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vicore Pharma Holding M&A Activity
Vicore Pharma Holding acquired XXX companies to date.
Last acquisition by Vicore Pharma Holding was on XXXXXXXX, XXXXX. Vicore Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vicore Pharma Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVicore Pharma Holding Investment Activity
Vicore Pharma Holding invested in XXX companies to date.
Vicore Pharma Holding made its latest investment on XXXXXXXX, XXXXX. Vicore Pharma Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vicore Pharma Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vicore Pharma Holding
| When was Vicore Pharma Holding founded? | Vicore Pharma Holding was founded in 2000. |
| Where is Vicore Pharma Holding headquartered? | Vicore Pharma Holding is headquartered in Sweden. |
| How many employees does Vicore Pharma Holding have? | As of today, Vicore Pharma Holding has over 29 employees. |
| Who is the CEO of Vicore Pharma Holding? | Vicore Pharma Holding's CEO is Ahmed Mousa. |
| Is Vicore Pharma Holding publicly listed? | Yes, Vicore Pharma Holding is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Vicore Pharma Holding? | Vicore Pharma Holding trades under VICO ticker. |
| When did Vicore Pharma Holding go public? | Vicore Pharma Holding went public in 2015. |
| Who are competitors of Vicore Pharma Holding? | Vicore Pharma Holding main competitors are Organogenesis, Santhera Pharma, Avalo Therapeutics, Zentalis Pharma. |
| What is the current market cap of Vicore Pharma Holding? | Vicore Pharma Holding's current market cap is $324M. |
| What is the current revenue of Vicore Pharma Holding? | Vicore Pharma Holding's last 12 months revenue is $463K. |
| What is the current revenue growth of Vicore Pharma Holding? | Vicore Pharma Holding revenue growth (NTM/LTM) is 367%. |
| What is the current EV/Revenue multiple of Vicore Pharma Holding? | Current revenue multiple of Vicore Pharma Holding is 426.1x. |
| Is Vicore Pharma Holding profitable? | No, Vicore Pharma Holding is not profitable. |
| What is the current EBITDA of Vicore Pharma Holding? | Vicore Pharma Holding has negative EBITDA and is not profitable. |
| What is Vicore Pharma Holding's EBITDA margin? | Vicore Pharma Holding's last 12 months EBITDA margin is (10279%). |
| What is the current EV/EBITDA multiple of Vicore Pharma Holding? | Current EBITDA multiple of Vicore Pharma Holding is (4.1x). |
| What is the current FCF of Vicore Pharma Holding? | Vicore Pharma Holding's last 12 months FCF is ($34M). |
| What is Vicore Pharma Holding's FCF margin? | Vicore Pharma Holding's last 12 months FCF margin is (7402%). |
| What is the current EV/FCF multiple of Vicore Pharma Holding? | Current FCF multiple of Vicore Pharma Holding is (5.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.